Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review)

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Antiangiogenic therapy is an elegant anticancer strategy that inhibits endothelial cell growth, leading to tumor hypoxia and starvation.
• However, tumor hypoxia is known to select for aggressive, metastatic cancer and is linked to poor prognosis.
• This creates a paradox where a well-tolerated therapy might inadvertently drive tumor progression.

Purpose of the Study:

• To reconcile the opposing effects of antiangiogenic therapy and tumor hypoxia.
• To re-evaluate the concept of "resistance to resistance" in the context of antiangiogenic agents.
• To explore hypoxia-inducible factor (HIF-1) as a therapeutic target to overcome resistance.

Main Methods:

• Review of existing literature on antiangiogenic therapy, tumor hypoxia, and cancer cell resistance mechanisms.
• Analysis of the role of hypoxia-inducible factor (HIF-1) in tumor survival, angiogenesis, and metastasis.
• Discussion of pharmacological approaches targeting HIF-1.

Main Results:

• While endothelial cells may not develop drug resistance, cancer cells can acquire resistance to hypoxia.
• Hypoxia-resistant cancer cells exhibit increased survival, resistance to apoptosis, and enhanced metastatic potential.
• Hypoxia-inducible factor (HIF-1) plays a critical role in enabling cancer cell survival under hypoxia and driving tumor angiogenesis.

Conclusions:

• Disrupting the HIF-1 pathway is a promising mechanism-based strategy to inhibit tumor growth and angiogenesis.
• Targeting HIF-1 offers a potential approach to overcome resistance to antiangiogenic therapies.
• Pharmacological inhibition of HIF-1 warrants further investigation as a novel anticancer strategy.